Browsing Tag
Novo Nordisk
103 posts
Novo Nordisk licenses Hengrui weekly oral GLP-1/GIP drug in deal worth up to $2.6bn
HRS-1596 adds an oral GLP-1/GIP dual agonist to Novo Nordisk’s external pipeline only days after the company licensed technology aimed at monthly and quarterly injections.
Hengrui lands $2.6bn Novo Nordisk deal for experimental weekly oral obesity drug
Novo Nordisk licenses Hengrui’s weekly oral GLP-1/GIP drug HRS-1596 for up to $2.6 billion as obesity competition intensifies.
Novo Nordisk signs €1.17bn Nanexa deal targeting monthly obesity injections
Novo Nordisk has licensed Nanexa's PharmaShell platform for as many as five programmes as competition shifts from weight loss alone toward convenience and dosing frequency.
Nanexa shares explode 122% after €1.17 billion Novo Nordisk injection deal
Nanexa shares more than doubled after Novo Nordisk signed a global licensing agreement worth up to €1.165 billion for technology designed to turn peptide medicines into monthly or quarterly injections.
Roche’s enicepatide delivers 15.5% weight loss in type 2 diabetes Phase II trial
The once-weekly GLP-1 and GIP medicine also brought blood sugar into the normal range for 62% of patients at its highest dose, supporting plans for broader Phase III development in 2027.
Scholar Rock keeps apitegromab FDA decision alive as Europe filing is reset
Scholar Rock has removed Catalent Indiana from the U.S. apitegromab application while keeping its September 30 FDA decision date intact, but the manufacturing issue has forced a European filing withdrawal and resubmission.
Mitsui’s Kassø e-methanol lands OMV as RFNBO offtaker, unlocking EU land fuel demand
Mitsui and European Energy added OMV as RFNBO offtaker for Kassø's e-methanol; four verticals now anchor a plant whose value lies in template, not tonnage.
Eli Lilly (NYSE: LLY) raises 2026 guidance as Mounjaro and Zepbound reshape pharma growth
Eli Lilly raises 2026 guidance as Mounjaro and Zepbound drive 48% Q2 revenue growth. Read how LLY’s GLP-1 scale reshapes Big Pharma.
Septerna’s oral hypoparathyroidism strategy gets its first human pharmacokinetic validation
SEP-479’s 3-to-4-day half-life supports once-daily dosing as Septerna targets an oral alternative in hypoparathyroidism. See what comes next.
Amgen data breach: Patient records exposed via third-party cloud storage
Amgen said patient health data was exfiltrated via third-party cloud storage in an incident deemed material days before its August 4 Q2 earnings release.